Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA)

This publication has 24 references indexed in Scilit:

• Gene therapy of streptozotocin‐induced diabetes by intramuscular delivery of modified preproinsulin genes
  The Journal of Gene Medicine, 2002
• Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine
  Gene Therapy, 2002
• Interleukin (Il)-4 Is a Major Regulatory Cytokine Governing Bioactive IL-12 Production by Mouse and Human Dendritic Cells
  The Journal of Experimental Medicine, 2000
• IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice
  Gene Therapy, 2000
• Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein
  Gene Therapy, 1999
• Activity and safety of DNA plasmids encoding IL-4 and IFN gamma
  Gene Therapy, 1999
• MHC Class I–Restricted CTL Responses to Exogenous Antigens
  Immunity, 1996
• Phase Ia Trial of a Polynucleotide Anti-Tumor Immunization to Human Carcinoembryonic Antigen in Patients with Metastatic Colorectal Cancer. University of Alabama at Birmingham, Birmingham, Alabama
  Human Gene Therapy, 1996
• Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production.
  The Journal of Experimental Medicine, 1995
• Can soluble antigens induce CD8+ cytotoxic T-cell responses? A paradox revisited
  Immunology Today, 1993